Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-03-06 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an official notification released via RNS (London Stock Exchange's news service) on March 6, 2025. The content explicitly details 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)' regarding the vesting of shares under a Deferred Bonus Plan and subsequent dividend reinvestment for executives like the CEO and CFO. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). The structure, including the RNS number and the detailed tables mandated by EU Market Abuse Regulation, confirms this classification.
2025-03-06 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2025-03-05 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is identified by the RNS Number header and contains a formal announcement regarding 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)'. Specifically, it details the granting of ordinary shares under incentive plans (AZDBP and AZPSP) to key executives (CEO and CFO). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing. The presence of the RNS Number and the regulatory context (EU Market Abuse Regulation) confirms it is a formal regulatory disclosure, but the specific content points strongly to DIRS.
2025-03-05 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2025-03-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details the total number of voting rights and issued share capital as of a specific date (28 February 2025), which is a mandatory disclosure under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of routine regulatory update, which is not a full report (like 10-K or IR) and doesn't fit specific categories like Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), falls best under the general 'Regulatory Filings' category (RNS) or potentially 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Since the core purpose is providing the denominator for voting rights calculations based on transparency rules, DVA is a strong candidate. However, given the structure and the explicit mention of RNS as the provider for general regulatory announcements, RNS is the most appropriate fallback/general regulatory classification if DVA is too specific for a routine update that isn't reporting the *results* of a vote, but rather the *basis* for future votes. Looking at the definitions, DVA is for 'Official results from shareholder votes'. This document is about the total voting rights capital base. Therefore, RNS (General Regulatory Filings) is the safest and most accurate classification for this routine transparency disclosure.
2025-03-03 English
IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN
Foreign Filer Report
2025-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.